| Patents for A61K 38 - Medicinal preparations containing peptides (316,240) |
|---|
| 03/26/2002 | US6362162 CML Therapy |
| 03/26/2002 | US6362161 Copolymer-1 improvements on compositions of copolymers |
| 03/26/2002 | US6362160 Immunophilin-binding agents prevent glutamate neurotoxicity associated with vascular stroke and neurodegenerative diseases |
| 03/26/2002 | US6362007 For diagnosis and therapy of systemic lupus erythematosus and related diseases, and diseases in which epstein-barr virus has been implicated |
| 03/26/2002 | US6362001 Establishing a culture of drosophila cells; transfecting with expressible class 1 mhc heavy chain gene linked to promoter; transfecting with an expressible .beta.-2 microglobulin gene and with assisting molecule gene, mixing with peptide |
| 03/26/2002 | US6362000 Providing to a mammalian cell a dna sequence encoding viral fusion protein operably linked to promoter active in cell; providing nucleic acid sequence of a retrovirus, nucleic acid sequence encoding gag protein; forming viral vector particles |
| 03/26/2002 | US6361994 Method for inhibiting angiogenesis and tumors with the isolated NC1 α1 chain monomer of type IV collagen |
| 03/26/2002 | US6361984 For therapy, diagnosis, and screening for diseases or conditions characterized by an abnormality in a signal transduction disorder |
| 03/26/2002 | US6361982 A dna obtained from streptomyces clavuligerus, which contains a biosynthesis regulatory gene; for large scale production of clavulanic acid antibiotics |
| 03/26/2002 | US6361977 Methods of using multivariant IL-3 hematopoiesis fusion protein |
| 03/26/2002 | US6361976 Co-administration of interleukin-3 mutant polypeptides with CSF'S for multi-lineage hematopoietic cell production |
| 03/26/2002 | US6361975 Mouse aspartic secretase-2(mASP-2) |
| 03/26/2002 | US6361971 A nucleotide sequence; diagnosis and therapy for central nervous system disorders, epilepsy, anxiety, depression, migraines, obesity, parkinson's disease and alzheimer's disease |
| 03/26/2002 | US6361970 A polypeptide encoding an isoleucyl trna synthetase; therapy and screening antibiotic compounds |
| 03/26/2002 | US6361968 Extension of a protein-protein interaction surface to inactive the function of a cellular protein |
| 03/26/2002 | US6361967 Axor10, a g-protein coupled receptor |
| 03/26/2002 | US6361965 YfiI pseudouridine synthase |
| 03/26/2002 | US6361954 Detection the presence or absence of human cell division cycle-6 protein in a sample by mixing a test sample with a specific antibody to the protein and detecting the complex formation |
| 03/26/2002 | US6361946 A bone marrow modulating method in mammals by adminstering a polypeptide that binds to at least one endothelial cell surface receptor to modulates myelopoiesis |
| 03/26/2002 | US6361938 Peptides which enhance transport across tissues and methods of identifying and using the same |
| 03/26/2002 | US6361797 Hydrogel compositions useful for the sustained release of macromolecules and methods of making same |
| 03/26/2002 | US6361778 Carboxyl terminal of papillomavirus L1 region is not required for formation of virus-like particles |
| 03/26/2002 | US6361776 Polypeptide isolated from mycobacterium vaccae comprising specified amino acid sequence, capable of eliciting and/or enhancing immune response to heterologous antigen |
| 03/26/2002 | US6361773 Antibodies produced against cytokine suppressive anti-inflammatory drug binding proteins |
| 03/26/2002 | US6361772 Human manganese superoxide dismutase DNA, its expression and method of recovering human manganese superoxide dismutase |
| 03/26/2002 | US6361771 Implantable cell culture device comprising semipermeable membrane permitting diffusion of growth factor therethrough, and arpe-19 cells genetically engineered to produce growth factor disposed within semipermeable membrane |
| 03/26/2002 | US6361770 Introducing ex vivo nucleic acid molecule comprising sequence encoding tap-1 into tumor cell, expressing tap-1 in tumor cell, permitting recognition of tumor by mammal's immune response, introducing tumor cell into mammal |
| 03/26/2002 | US6361769 Stimulation of host defense mechanisms against viral challenges |
| 03/26/2002 | US6361760 Aerosol composition comprising tricyclic compound or pharmaceutically acceptable salt thereof, liquefied hydrofluoroalkane and medium-chain fatty acid triglyceride |
| 03/26/2002 | CA2180570C Isolated p27 protein and its encoding nucleic acid molecules |
| 03/26/2002 | CA2176670C 15-deoxyspergualin analogs, their method of preparation and their use in therapeutics |
| 03/26/2002 | CA2144514C Morphogen-induced liver regeneration |
| 03/26/2002 | CA2137551C A novel endothelial cell molecule mediating lymphocyte binding in man |
| 03/26/2002 | CA2118136C Partially modified and retro-inverted tetrapeptides analogues of c-reactive protein fragments |
| 03/26/2002 | CA2051260C Anti-oxidant system based on a basic amino acid associated with at least one tocopherol or one of its derivatives and at least one non-thiolated polypeptide, and compositions containing such an anti-oxidant system |
| 03/26/2002 | CA2027665C Agent for preventing and treating opacity of lens |
| 03/26/2002 | CA1341351C Production of chimeric mouse-human antibodies with specificity to human tumor antigens |
| 03/22/2002 | CA2357526A1 Mannosidase structures |
| 03/21/2002 | WO2002023184A1 Method for treatment of insulin resistance in obesity and diabetes |
| 03/21/2002 | WO2002022862A2 Methods for identifying modulators of protein interactions |
| 03/21/2002 | WO2002022848A2 Compositions comprising mixtures of human cytokines and methods of producing the same |
| 03/21/2002 | WO2002022840A1 Antisense modulation of madh6 expression |
| 03/21/2002 | WO2002022832A1 A cell line expressing mutated human tissue - type plasminogen activator, the constructing strategy thereof and method of preparing expressed protein |
| 03/21/2002 | WO2002022820A1 Inhibition of stenosis or restenosis by p-selectin antagonists |
| 03/21/2002 | WO2002022819A2 Calcium binding proteins |
| 03/21/2002 | WO2002022818A1 Human and rat pgc-3, ppar-gamma coactivations and splice variants thereof |
| 03/21/2002 | WO2002022817A2 Nuclear receptor l66 and methods of use |
| 03/21/2002 | WO2002022815A1 Methods and materials relating to neuropilin-like polypeptides and polynucleotides |
| 03/21/2002 | WO2002022808A2 Cripto mutant and uses thereof |
| 03/21/2002 | WO2002022807A2 Dermatophagoides nucleic acid molecules, proteins and uses thereof |
| 03/21/2002 | WO2002022806A2 Isolated human phospholipase proteins, nucleic acid molecules encoding human phospholipase proteins, and uses tehreof |
| 03/21/2002 | WO2002022805A2 Modulation of il-2- and il-15-mediated t cell responses |
| 03/21/2002 | WO2002022803A2 Peptide epitopes recognized by antigen specific cd4+ t lymphocytes |
| 03/21/2002 | WO2002022802A1 Novel compounds |
| 03/21/2002 | WO2002022801A2 Mammalian receptor genes and uses |
| 03/21/2002 | WO2002022795A2 Isolated human kinase proteins, nucleic acid molecules and uses thereof |
| 03/21/2002 | WO2002022792A2 Nucleic acid molecules encoding a poly(adp-ribose) polymerase |
| 03/21/2002 | WO2002022791A2 Regulation of human pyridoxine 5'-phosphate oxidase |
| 03/21/2002 | WO2002022782A2 Homologous 28-kilodalton immunodominant protein genes of ehrlichia canis and uses thereof |
| 03/21/2002 | WO2002022777A2 Cellular genes involved in oncogenesis, products of said genes and their diagnostic and therapeutic uses |
| 03/21/2002 | WO2002022776A2 Human coagulation factor vii variants |
| 03/21/2002 | WO2002022686A2 Defensin-antigen fusion proteins |
| 03/21/2002 | WO2002022685A2 Muc1 extracellular domain and cancer treatment compositions and methods derived therefrom |
| 03/21/2002 | WO2002022684A2 Transporters and ion channels |
| 03/21/2002 | WO2002022682A1 Interferon-alpha induced gene |
| 03/21/2002 | WO2002022680A2 Site-specific, antibody-mediated activation of proapoptotic cytokine: amaice (antibody-mediated apoptosis inducing cytokine) |
| 03/21/2002 | WO2002022679A2 Variants of phleum pratense allergenic proteins |
| 03/21/2002 | WO2002022678A2 Isolated human transporter proteins, nucleic acid molecules encoding human transporter proteins, and uses thereof |
| 03/21/2002 | WO2002022677A2 Variants of allergenic proteins of the group 2 of dermatophagoides |
| 03/21/2002 | WO2002022676A1 A longevity guarantee protein and its encoding sequence and use |
| 03/21/2002 | WO2002022665A1 Novel g protein-coupled receptor proteins and dnas tehreof |
| 03/21/2002 | WO2002022663A2 Stress resistant retroviruses |
| 03/21/2002 | WO2002022661A2 NOVEL PDEs AND USES THEREOF |
| 03/21/2002 | WO2002022660A2 Novel nucleic acids and polypeptides |
| 03/21/2002 | WO2002022659A2 DISCRIMINATION BETWEEN GnRH-I AND GnRH-II |
| 03/21/2002 | WO2002022658A2 Muteins of the cgrp 1-7 peptide fragment and use thereof as nicotinic neuronal receptor enhancers |
| 03/21/2002 | WO2002022657A2 Peptide antagonist of multiple chemokine receptors and uses thereof |
| 03/21/2002 | WO2002022656A2 An hsp70 peptide stimulating natural killer (nk) cell activity and uses thereof |
| 03/21/2002 | WO2002022655A1 Glutathione conjugates with distamycin derivatives having antitumoral activity |
| 03/21/2002 | WO2002022642A1 Antisense insulin-like growth factor binding protein (igfbp)-2-oligodeoxynucleotides for prostate and other endocrine tumor therapy |
| 03/21/2002 | WO2002022641A1 Antisense modulation of caspase 9 expression |
| 03/21/2002 | WO2002022640A1 Antisense modulation of caspase 7 expression |
| 03/21/2002 | WO2002022639A1 Antisense modulation of btak expression |
| 03/21/2002 | WO2002022638A1 22 human secreted proteins |
| 03/21/2002 | WO2002022637A1 Antisense modulation of phosphorylase kinase beta expression |
| 03/21/2002 | WO2002022636A1 Antisense modulation of her-2 expression |
| 03/21/2002 | WO2002022635A1 Antisense modulation of clusterin expression |
| 03/21/2002 | WO2002022573A2 Methods and compositions relating to hydrogen peroxide and superoxide production by antibodies |
| 03/21/2002 | WO2002022571A2 Compounds and methods for inhibiting alpha-1 beta-1 integrins |
| 03/21/2002 | WO2002022553A2 Non-natural basic amino acids, their preparation and use |
| 03/21/2002 | WO2002022212A2 Combination therapy for treatment of autoimmune diseases using b cell depleting/immunoregulatory antibody combination |
| 03/21/2002 | WO2002022211A2 Reduction of the electrocardiographic ot interval |
| 03/21/2002 | WO2002022177A2 High efficiency cardiac gene transfer |
| 03/21/2002 | WO2002022176A1 Method of modulating neovascularization |
| 03/21/2002 | WO2002022175A2 Method and composition for treating tumors by selective induction of apoptosis |
| 03/21/2002 | WO2002022174A1 A novel cationic lipopolymer as biocompatible gene delivery agent |
| 03/21/2002 | WO2002022170A1 Insulin secretion controlling agents |
| 03/21/2002 | WO2002022169A2 VECTORS FOR MOLECULE DELIVERY TO CD11b EXPRESSING CELLS |
| 03/21/2002 | WO2002022166A2 Tweak receptor agonists as anti-angiogenic agents |
| 03/21/2002 | WO2002022163A1 Remedies for ischemic diseases |